Why is greater medication adherence associated with better outcomes

Area of Science:

• Clinical Trials and Observational Research
• Epidemiology and Public Health
• Medical Treatment Efficacy

Background:

• Previous research indicated a link between higher placebo adherence and improved health outcomes.
• The Women's Health Initiative (WHI) provided data from over 27,000 subjects in two randomized controlled trials.
• Over 800 risk factors were analyzed to understand the placebo adherence-outcome association.

Purpose of the Study:

• To investigate if adherence to placebo medication is explained by other medication adherence, healthcare behaviors, disease risk, or predicted adherence.
• To determine the factors influencing the observed association between placebo adherence and health outcomes.

Main Methods:

• Analysis of data from 27,347 subjects in two randomized controlled trials (RCTs) of hormone therapy within the Women's Health Initiative (WHI).
• Examination of over 800 potential risk factors, including adherence to other medications, healthcare behaviors, and disease risk.
• Statistical assessment of the predictive power of WHI risk factors on placebo adherence.

Main Results:

• Higher placebo adherence was significantly associated with reduced risk of death, myocardial infarction, stroke, and breast cancer.
• No significant association was found between placebo adherence and colon cancer risk.
• Adherence to hormone therapy showed only a weak association with outcomes.
• WHI risk factors poorly predicted placebo adherence, explaining less than 4% of the variance (R² < 4%).
• No measured underlying factors accounted for the placebo adherence-outcome association.

Conclusions:

• Adherence to placebo appears to be a marker for unmeasured, significant risk factors.
• Identifying these unmeasured risk factors could enhance the validity of observational studies.
• Reducing unmeasured confounding is crucial for improving the reliability of medical treatment research.